



## Anika to Issue Fourth-Quarter and Full-Year 2018 Financial Results and Business Highlights on Thursday, February 21

BEDFORD, Mass.--(BUSINESS WIRE)--Feb. 7, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its fourth-quarter and full-year 2018 financial results after the close of the market on Thursday, February 21, 2019 and hold its investor conference call on the same day, Thursday, February 21, 2019, at 5:00 p.m. ET to discuss its financial results, business highlights, and outlook.

The conference call can be accessed by dialing 1-855-468-0611 (toll-free domestic) or 1-484-756-4332 (international). A live audio webcast will be available in the "Investor Relations" section of Anika's website, [www.anikatherapeutics.com](http://www.anikatherapeutics.com). An accompanying slide presentation also can be accessed via the Anika Therapeutics website. The call will be archived and accessible on the same website shortly after its conclusion.

About Anika Therapeutics, Inc.

[Anika Therapeutics, Inc.](#) (NASDAQ: ANIK) is a global, integrated orthopedic and regenerative medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative tissue repair. The Company has over two decades of global expertise developing, manufacturing, and commercializing more than 20 products based on its proprietary [hyaluronic acid \(HA\) technology](#). Anika's orthopedic medicine portfolio includes [ORTHOVISC®](#), [MONOVISC®](#), and [CINGAL®](#), which alleviate pain and restore joint function by replenishing depleted HA, and [HYALOFAST](#), a solid HA-based scaffold to aid cartilage repair and regeneration. For more information about Anika, please visit [www.anikatherapeutics.com](http://www.anikatherapeutics.com).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190207005040/en/>

Source: Anika Therapeutics, Inc.

For Investor Inquiries:  
Anika Therapeutics, Inc.  
Sylvia Cheung, 781-457-9000  
Chief Financial Officer

For Media Inquiries:  
W2O Group  
Sonal Vasudev, 917-523-1418  
[sonal@w2ogroup.com](mailto:sonal@w2ogroup.com)